{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:42:01Z","timestamp":1765233721450,"version":"3.28.0"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1055\/a-2166-6824","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T23:46:57Z","timestamp":1707349617000},"page":"136-141","source":"Crossref","is-referenced-by-count":1,"title":["Diabetes and Fatty Liver"],"prefix":"10.1055","volume":"132","author":[{"given":"Norbert","family":"Stefan","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research (DZD), Germany"},{"name":"Heisenberg Professorship and Chair of Clinical Experimental\n                    Diabetology, Department of Internal Medicine IV, Endocrinology, Diabetology, and\n                    Nephrology, University Hospital, T\u00fcbingen, Germany"},{"name":"Department of Pathophysiology of Prediabetes of the Institute for\n                    Diabetes Research and Metabolic Diseases (IDM) of Helmholtz Centre Munich at the\n                    University of T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[{"name":"German Center for Diabetes Research (DZD), Germany"},{"name":"Division for Endocrinology and Diabetology, Medical Faculty of the\n                    Heinrich Heine University and University Hospital, D\u00fcsseldorf,\n                    Germany"},{"name":"Institute for Clinical Diabetology, German Diabetes Center (DDZ),\n                    Leibniz Center for Diabetes Research at the Heinrich Heine University,\n                    D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease \u2013 A global public health\n                    perspective","volume":"70","author":"Z M Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/L19-0635","article-title":"Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint\n                    Blockade","volume":"172","author":"T Eigentler","year":"2020","journal-title":"Ann Intern Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain,\n                    United Kingdom, and United States for the period 2016-2030","volume":"69","author":"C Estes","year":"2018","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic\n                    consequences, and treatment strategies","volume":"7","author":"N Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset\n                    diabetes: a 5-year follow-up study","volume":"7","author":"O P Zaharia","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment\n                    of prevalence, incidence, and outcomes","volume":"64","author":"Z M Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1055\/a-1880-2283","article-title":"Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen\n                    Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und\n                    Stoffwechselkrankheiten (DGVS) \u2013 April 2022 \u2013\n                    AWMF-Registernummer: 021-025","volume":"60","author":"E Roeb","year":"2022","journal-title":"Z Gastroenterol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","article-title":"EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic\n                    fatty liver disease","volume":"59","author":"European Association for the Study of the Liver (EASL);\n                            European European Association for the Study of the Liver (EASL);\n                            European Association for the Study of Diabetes (EASD); European\n                            Association for the Study of Obesity (EASO)","year":"2016","journal-title":"Diabetologia"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver\n                    disease severity and prognosis \u2013 2021 update","volume":"75","author":"European Association for the Study of the Liver","year":"2021","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/apt.15830","article-title":"Clinical assessment for high-risk patients with non-alcoholic fatty liver\n                    disease in primary care and diabetology practices","volume":"52","author":"Z M Younossi","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"H Tilg","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice\n                    guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"N Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/jim-2018-000864","article-title":"Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic\n                    cohort of patients with type 2 diabetes mellitus","volume":"67","author":"F Bril","year":"2019","journal-title":"J Investig Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty\n                    liver disease","volume":"158","author":"M Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"M Roden","year":"2019","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and\n                    diabetes","volume":"10","author":"N Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease\n                    nomenclature","volume":"78","author":"Rinella ME, Lazarus JV, Ratziu V et al.","year":"2023","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic\n                    steatohepatitis: a systematic review and metaanalysis of paired-biopsy\n                    studies","volume":"13","author":"S Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular\n                    disease and other extrahepatic diseases","volume":"66","author":"L A Adams","year":"2017","journal-title":"Gut"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular\n                    Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis","volume":"326","author":"A Aminian","year":"2021","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic\n                    steatohepatitis","volume":"384","author":"P N Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic\n                    steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2\n                    trial","volume":"8","author":"R Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"S M Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a\n                    multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"S A Harrison","year":"2019","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH","volume":"389","author":"R Loomba","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Experimental and Clinical Endocrinology & Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2166-6824.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T14:32:52Z","timestamp":1730817172000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2166-6824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":25,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2024,3,21]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2166-6824","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"type":"print","value":"0947-7349"},{"type":"electronic","value":"1439-3646"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}